Our Therapies

NEXVIAZYME® Infusion Therapy

Violet Health Outpatient Specialty Infusion Care

About NEXVIAZYME® Infusion Therapy

NEXVIAZYME® (avalglucosidase alfa-ngpt) is an enzyme replacement therapy for Pompe disease. People with Pompe disease are missing enough of an enzyme called acid alpha-glucosidase, or GAA, whose job is to break down glycogen inside the lysosome, the cell's recycling compartment. Without it, glycogen builds up year after year inside muscle cells and gradually damages them. The muscles that suffer most are the ones that never get a day off: the legs, the trunk, and the diaphragm. NEXVIAZYME® supplies a manufactured version of that enzyme by infusion, so the cell has something to clear the backlog with.

The engineering detail is what separates it from the older enzyme therapy. Getting an enzyme into the bloodstream is straightforward. Getting it inside a muscle cell is the hard part, and that depends on mannose-6-phosphate tags that act like a key for the receptor on the cell surface. Avalglucosidase alfa-ngpt carries roughly 15 times more of those tags than alglucosidase alfa, which is the whole point of the molecule: more enzyme reaching the tissue that needs it rather than circulating past it.

What this therapy does and does not do

This is replacement, not repair. NEXVIAZYME® does not correct the genetic variant that causes Pompe disease, and it does not rebuild muscle that has already been lost. It replaces a missing enzyme for as long as it keeps being given, which means treatment is lifelong and there is no maintenance phase that stretches the interval out or a planned stopping point. In that respect it is closest on this site to ZEMAIRA® and the other alpha-1 augmentation products: a protein the body cannot make, supplied from outside on a fixed schedule, to protect the tissue that is still there.

Dosing and administration

Given by intravenous infusion once every two weeks, with the dose calculated from actual body weight.
Patients weighing 30 kg or more: 20 mg/kg every two weeks. Patients weighing less than 30 kg: 40 mg/kg every two weeks.
That two-tier rule runs the opposite way to what most people expect, since the smaller patient receives the higher dose per kilogram. It reflects how the enzyme distributes in smaller bodies, and it means a growing child crossing 30 kg has the dose recalculated downward per kilogram rather than up.
Supplied as 100 mg single-dose vials of lyophilized powder, reconstituted with sterile water to 10 mg/mL and then diluted in 0.9% sodium chloride for infusion through an in-line filter.
The infusion starts slowly at 1 mg/kg/hour and steps up every 30 minutes if there is no sign of a reaction. Total time is roughly 4 to 5 hours for most adults and up to 7 hours for the smallest patients on the first infusions.
Premedication with antihistamines, antipyretics, or corticosteroids is considered rather than required, and the decision is made per patient by the prescriber.

Switching from alglucosidase alfa

Most patients starting NEXVIAZYME® are not new to enzyme replacement. They are moving across from alglucosidase alfa (LUMIZYME®), and that switch is unusually clean: there is no washout period between the last dose of the old therapy and the first dose of the new one, the every-two-weeks rhythm stays the same, and for patients already at 20 mg/kg the dose number does not change either. What changes is the molecule and, in practice, the infusion rate schedule, since the ramp restarts from the beginning.

What the trials showed

Approval rested on COMET, a 49-week randomized, double-blind trial in 100 treatment-naive adults with late-onset Pompe disease, comparing NEXVIAZYME® 20 mg/kg with alglucosidase alfa 20 mg/kg every two weeks. The primary measure was upright forced vital capacity, a breathing test that tracks diaphragm strength. It improved by 2.9 percentage points of predicted on NEXVIAZYME® against 0.5 on the comparator. Walking distance on the six-minute walk test improved by about 32 meters against 2 meters. Urinary Glc4, a marker of glycogen breakdown, fell by roughly half.

Read those numbers in context. NEXVIAZYME® met the bar for being no worse than the existing therapy, and the statistical test for being better was not formally met, though every measure pointed the same direction. The comparison was against active treatment rather than placebo, so both groups were being treated. In a condition where untreated breathing function declines steadily, holding ground is the baseline expectation and small gains are meaningful.

Conditions treated by this therapy

NEXVIAZYME® is FDA approved for a single indication:

Patients 1 year of age and older with late-onset Pompe disease, also described as lysosomal acid alpha-glucosidase (GAA) deficiency.

Pompe disease is rare, inherited, and highly variable. Late-onset disease can appear in a toddler or in someone in their sixties, and it is often mistaken for a muscular dystrophy or a limb-girdle weakness for years before a GAA enzyme assay and genetic testing settle the question. The label is written around that variability: it sets an age floor and a diagnosis, and nothing about severity, walking status, or ventilator use.

Who this therapy is not for

Infants with infantile-onset Pompe disease. The U.S. indication covers late-onset disease from 1 year of age, and infantile-onset disease is treated with alglucosidase alfa (LUMIZYME®).
Children under 1 year of age, where safety and effectiveness have not been established.
Other glycogen storage diseases and other causes of limb-girdle weakness. This therapy replaces one specific enzyme and does nothing for a deficiency of any other.
People found to carry GAA variants or a pseudodeficiency allele without clinical disease. A confirmed diagnosis, not a screening result alone, is what starts treatment.

A note on where this sits among the options. Pompe disease now has more than one enzyme therapy: alglucosidase alfa (LUMIZYME®), avalglucosidase alfa (NEXVIAZYME®), and cipaglucosidase alfa given with the oral stabilizer miglustat (POMBILITI® with OPFOLDA®). They are given on the same two-week rhythm but differ in molecule, dose, and whether an oral companion drug is involved, so a switch between them is a prescriber decision rather than a scheduling one.

Because Pompe disease is rare and long-term data matter, patients and families are encouraged to enroll in the Pompe Registry. Participation is voluntary and your care team can help you sign up.

NEXVIAZYME® Price

The cost of prescription medications can vary depending on your insurance coverage. If you're concerned about the price of your medication:

Contact your insurance provider to understand your coverage
Ask your doctor or pharmacist about lower-cost alternatives
Check with the drug manufacturer about financial assistance programs
Explore patient assistance options if you're uninsured or underinsured

Remember, many resources exist to help patients access necessary medications. Don't hesitate to ask for help if you're struggling with medication costs. No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our Violet Health team.

What to Expect During NEXVIAZYME® Infusion Therapy

At Violet Health we're proud to offer NEXVIAZYME® in our spa-like infusion center, a comfortable alternative to traditional hospital settings. That matters more here than almost anywhere else on this site, because this is a long appointment that repeats every two weeks for the rest of your life. The room, the chair, and the people are not a detail when you add up 26 visits a year.

Plan on most of a day. Adults generally finish the infusion in 4 to 5 hours, and smaller patients on the higher per-kilogram dose can take up to 7 hours on early visits. Here is how a visit runs:

Weight is taken at every visit, since the dose is calculated from actual body weight and the dose tier changes at 30 kg.
If premedication has been prescribed, it is given before the infusion starts.
The infusion begins at 1 mg/kg/hour and the rate is increased in steps every 30 minutes as long as you are tolerating it. Nothing has gone wrong if the nurse holds a step longer.
Vital signs are checked frequently throughout, and more often than on most therapies here. A nurse stays close for the whole infusion.
You are observed after the infusion finishes. The length of that window depends on your history and how previous infusions have gone.
Eat and drink normally beforehand. There is no fasting requirement. Bring lunch, a charger, headphones, and something to do.

Why the first infusions take the longest

The rate ramp is the clock here, not the volume. Early infusions follow a four-step schedule that climbs from 1 mg/kg/hour to 7 mg/kg/hour. Once you have tolerated several infusions, a five-step schedule reaching 10 mg/kg/hour may be used for smaller patients, which shortens a 7-hour infusion to about 5. Patients switching from alglucosidase alfa start the ramp from the beginning even though they are experienced with infusions, so expect the first NEXVIAZYME® visit to run longer than the one it replaced.

Breathing, positioning, and comfort

Pompe disease weakens the diaphragm, and many patients breathe less comfortably lying flat, use noninvasive ventilation at night, or need a specific chair position to stay comfortable for hours. Tell us at booking about ventilation and cough-assist equipment, transfer needs, preferred positioning, and any mobility aids coming with you. Sitting upright for a long infusion is only tolerable if that is planned ahead of arrival rather than improvised at the chair. If you use overnight ventilation, bring your usual setup if your visit may run into the evening.

The fluid matters too

An infusion of this size delivers a real volume of fluid, between 100 and 700 mL depending on weight. For patients with heart or breathing problems, or anyone on a fluid restriction, that volume is part of the risk rather than an afterthought. Make sure your care team knows about any cardiac history, fluid restriction, or diuretic use before the first dose.

How progress is measured

Response is tracked with breathing tests, walking tests, and strength measures rather than how you feel on a given day, usually every 6 to 12 months through your Pompe or neuromuscular center. Urinary Glc4, a marker of glycogen breakdown, may also be followed. Improvement is gradual and measured over a year, not a month. For many patients the honest goal is slowing or stopping a decline that was already underway, and a flat line on a test that had been falling is a result worth recognizing.

Physical therapy, respiratory therapy, and exercise guidance continue alongside treatment. Enzyme replacement clears the glycogen; the rest of the program is what turns that into function.

Boxed Warning

NEXVIAZYME® carries a boxed warning, the FDA's most serious form of labeling, covering three related risks. All three are about the infusion itself rather than long-term exposure, which is why the visit is staffed and monitored the way it is.

Severe hypersensitivity reactions, including anaphylaxis

Life-threatening allergic reactions, including anaphylaxis, have occurred. Resuscitation equipment and trained staff are available throughout every infusion. If a severe reaction occurs the infusion is stopped immediately and treated. Whether to give the drug again afterward is weighed case by case, and for some patients a gradual desensitization procedure is considered.

Infusion-associated reactions

Severe infusion-associated reactions have also occurred. These can look like flushing, hives, itching, headache, nausea, chills, chest discomfort, a change in blood pressure, or shortness of breath, and they typically appear while the drug is running or shortly after. Being unwell on the day, with an active infection for example, raises the risk, and patients with advanced Pompe disease have less cardiac and respiratory reserve to absorb a reaction. Mild and moderate reactions are usually managed by slowing or pausing the infusion rather than abandoning it.

Risk of acute cardiorespiratory failure in susceptible patients

This is the part specific to Pompe disease. Patients prone to fluid overload, those with an acute respiratory illness, and those with compromised heart or lung function for whom fluid restriction is advised can have a serious worsening of their cardiac or respiratory status during the infusion. Vital signs are monitored more frequently for these patients. If you are unwell with a chest infection, call before your appointment rather than arriving for it: postponing a dose by a few days is a normal and safe decision.

Premedication with an antihistamine, a fever reducer, or a corticosteroid may be used to reduce the chance of a reaction, but it is considered rather than mandatory, and reactions can still happen despite it.

NEXVIAZYME® Side Effects

The most common side effects, reported in more than 5% of patients, were:

Headache, fatigue, and dizziness
Diarrhea, nausea, and vomiting
Joint pain and muscle pain
Itching, hives, and redness or flushing of the skin
Shortness of breath and pins and needles

Most of this list belongs to the infusion, not the days in between

Read that list again and the pattern is clear: headache, flushing, hives, itching, nausea, chills, and breathlessness are the vocabulary of an infusion reaction. Most of what patients experience on this therapy happens in the chair, while staff are watching, and settles when the rate is slowed. That is a genuinely different shape of risk from the immune suppression, organ toxicity, or long-term monitoring that defines most other pages on this site. There is no four-year lab schedule and no infection prophylaxis here. The attention is concentrated into the hours of the infusion.

Antibodies to the enzyme

Nearly all patients who have not had enzyme therapy before develop antibodies to avalglucosidase alfa, with a median time to seroconversion of about 8 weeks. This sounds alarming and usually is not: most patients continue treatment without a change in how well it works. High antibody levels can reduce response or raise the chance of reactions, so antibody testing may be done if infusions become harder to tolerate or if measured progress stalls. One practical consequence of the shared biology is that antibodies to alglucosidase alfa cross-react with avalglucosidase alfa, so an antibody history from previous enzyme therapy is relevant information when switching.

Call your care team right away if you experience:

Hives, rash, swelling of the face, lips, or tongue, wheezing, chest tightness, or trouble breathing during or after an infusion
Lightheadedness, fainting, a racing heart, or feeling suddenly unwell in the hours after a visit
More breathlessness than usual, new swelling in the legs, or any increase in your ventilation or cough-assist needs
Fever, a change in cough, or increased secretions, especially in the days before a scheduled infusion

Important Safety Information

NEXVIAZYME® has no contraindications. There is no screening panel to clear, no restricted distribution program, and no washout required when switching from another enzyme therapy. The entire warnings section is the boxed warning, which means the safety plan for this drug is the way the infusion is run rather than a list of things to rule out first.

Pregnancy and nursing

There is no contraception window on this label, which sets it apart from most therapies on this site. Available human data are not sufficient to identify a risk, and in animal studies the enzyme did not cross the placenta, though embryofetal loss was seen in mice at high exposures in the setting of a maternal allergic response. That is the reasoning behind the advice: the concern in pregnancy is a severe infusion reaction in the mother rather than a direct effect on the fetus. There are no data on the enzyme in human milk. Untreated Pompe disease carries real risks in pregnancy too, so the decision to continue, pause, or adjust treatment is made with your prescriber rather than by rule.

Use in specific populations

Children: established from 1 year of age for late-onset disease. Not established below 1 year.
Older adults: clinical trials included patients into their seventies, and no separate dose adjustment is specified for age.
Kidney or liver impairment: no dose adjustment is expected, since the enzyme is broken down into peptides and amino acids rather than cleared by the kidneys or metabolized by the liver.
Drug interactions: none have been established, and no interaction studies are required for a protein of this kind.

Before you start, tell your care team if you

Have ever had a reaction to alglucosidase alfa, cipaglucosidase alfa, or any other infused protein therapy, and what happened
Have heart disease, heart failure, or a fluid restriction, or take a diuretic
Use noninvasive ventilation or cough assist, or have had repeated chest infections or respiratory failure
Are unwell on the day of an infusion, particularly with a fever or a chest infection
Are pregnant, planning a pregnancy, or breastfeeding

Keep the Medication Guide, and do not stop treatment without speaking to your prescriber first. Because this is replacement therapy, the benefit lasts only as long as the infusions continue.

What Your Referral Should Include

NEXVIAZYME® referrals turn on two things: a confirmed diagnosis, and enough cardiac and respiratory detail to plan a long infusion safely. A complete referral should include:

Confirmed diagnosis of late-onset Pompe disease, with the GAA enzyme activity result and genetic testing identifying the GAA variants. A newborn screening result or a single enzyme assay without confirmation is not sufficient
Date of birth and current weight with the date it was measured, since the dose tier changes at 30 kg and the dose is recalculated as a child grows
Prior enzyme replacement therapy: which product, dose, how long, the date of the last dose, and any reactions. Note that no washout is required when switching from alglucosidase alfa
Any known antibody status from previous enzyme therapy, including cross-reactive immunologic material status if tested, since antibodies to alglucosidase alfa cross-react with this enzyme
Baseline pulmonary function, ideally upright and supine forced vital capacity with dates, plus use of noninvasive ventilation, cough assist, or tracheostomy
Baseline motor function, including six-minute walk distance where available, ambulatory status, and mobility aids used
Cardiac history and any fluid restriction or diuretic use, which directly affects how the infusion volume is managed
Allergy and reaction history, including any prior anaphylaxis or reactions to infused protein therapies
The premedication plan, if one is intended, with agents and timing
Venous access notes, including any history of difficult access or an existing port or central line, since this is an infusion every two weeks for life
Mobility and handling notes: transfer method, positioning preferences, and equipment arriving with the patient for a visit of several hours
Swallowing and nutrition status if relevant, and baseline creatine kinase if available
For patients of reproductive potential, pregnancy status and whether treatment during pregnancy has been discussed
The managing Pompe or neuromuscular center, who performs the periodic pulmonary and motor assessments, and Pompe Registry enrollment status
For patients under 18, the caregiver or guardian who will attend appointments and the preferred contact for scheduling